Ardelyx (ARDX) Other Non-Current Liabilities (2013 - 2026)
Ardelyx (ARDX) posted Other Non-Current Liabilities of $25.9 million for Q1 2026, little changed on a QoQ basis from $25.9 million in Q4 2025, and down 2.48% year-over-year from $26.5 million in Q1 2025.
Ardelyx (ARDX) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Ardelyx's Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $25.9 million for Q1 2026.
- Quarterly Other Non-Current Liabilities fell 2.48% year-over-year to $25.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.9 million (down 2.48% YoY) and the FY2025 annual result came in at $25.9 million, up 1.37% from the prior year.
- Other Non-Current Liabilities was $25.9 million for Q1 2026 at Ardelyx, roughly flat from $25.9 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $28.6 million in Q3 2025 and bottomed at $170000.0 in Q3 2023.
- A 5-year average of $19.2 million and a median of $22.5 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities plunged 98.37% — and 2024, when it surged 14236.47%.
- Ardelyx's Other Non-Current Liabilities stood at $11.3 million in 2022, then jumped by 79.31% to $20.2 million in 2023, then gained by 26.5% to $25.5 million in 2024, then gained by 1.37% to $25.9 million in 2025, then retreated by 0.05% to $25.9 million in 2026.
- Business Quant data shows ARDX's Other Non-Current Liabilities at $25.9 million in Q1 2026, $25.9 million in Q4 2025, and $28.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Ardelyx | 1.26 Bn | 1.02 Bn | 89.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.86 Mn |
| Dec 31, 2025 | 25.88 Mn |
| Sep 30, 2025 | 28.63 Mn |
| Jun 30, 2025 | 27.76 Mn |
| Mar 31, 2025 | 26.52 Mn |
| Dec 31, 2024 | 25.53 Mn |
| Sep 30, 2024 | 24.37 Mn |
| Jun 30, 2024 | 23.10 Mn |
| Mar 31, 2024 | 21.88 Mn |
| Dec 31, 2023 | 20.18 Mn |
| Sep 30, 2023 | 170,000.00 |
| Jun 30, 2023 | 13.19 Mn |
| Mar 31, 2023 | 12.22 Mn |
| Dec 31, 2022 | 11.25 Mn |
| Sep 30, 2022 | 10.42 Mn |
| Jun 30, 2022 | 9.59 Mn |
| Dec 31, 2020 | 1.38 Mn |
| Sep 30, 2020 | 1.26 Mn |
| Jun 30, 2020 | 1.12 Mn |
| Mar 31, 2020 | 1.05 Mn |